PRF + Minocycline vs Arestin in Non-surgical Perio Therapy

Periodontitis is a chronic, biofilm-modulated inflammatory disease characterized by microbial dysbiosis and a dysregulated host immune response, eventually resulting in the gradual breakdown of the periodontal attachment apparatus. While non-surgical periodontal therapy (NSPT) remains the first choice of treatment, its capability to completely resolve inflammation and pocketing in moderate disease severity may be limited, supporting the use of adjunctive antimicrobial or biologic interventions. Platelet-rich fibrin (PRF) and locally administered antibiotics, including minocycline, have individually shown clinical advantages; nonetheless, evidence assessing their combined utility remains unexplored. This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride (Arestin) as adjuncts to NSPT in patients with Stage II or III, Grade A or B periodontitis.

Inclusion criteria

• Male and Female subjects requiring non-surgical periodontal therapy• No contraindications to periodontal treatment

Exclusion criteria

• previous periodontal treatment within the past 6 months;
• local or systemic antibiotic treatment within the past 3 months;
• diagnosis of Stage I/ or IV periodontitis;
• poor oral hygiene defined as a full-mouth plaque score >30%;
• history of radiation or immunosuppressive therapy;
• presence of neurologic disorders, major mechanical obstruction to mouth opening, or acute temporomandibular capsulitis;
• systemic conditions that may compromise bone metabolism or wound healing such as metabolic bone disease, uncontrolled diabetes;
• history of substance abuse such as drug or alcohol; or
• current pregnancy, nursing, or planning pregnancy during the study period.